Vaxxas announced today that it was granted an exclusive license for a next-generation COVID-19 vaccine to be used with its delivery patch. Cambridge, Massachusetts-based Vaxxas received the license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine. The license comes with a companion background technology license from the U.S. National […]
Vaxxas
HHS gives Vaxxas $22M to support vaccine patch tech
Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]
Could Vaxxas’ tiny patches enable a better COVID-19 vaccine?
Tiny vaccine delivery patches could solve logistical challenges, but they face manufacturing hurdles. Here’s how Vaxxas is trying to overcome them. Merck (NYSE:MRK) and Vaxxas announced earlier this year that the pharmaceutical giant was using Vaxxas’ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate. Vaxxas did not disclose what […]
Merck eyes tiny patches as a vaccine delivery method
Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans […]
